ArticleTheranostics2022

SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.

Li Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.